What We're Reading: Page 99
Industry reads hand-picked by our editors
Oct 20, 2022
-
The Wall Street Journal
Drugmakers Look to Limit Medicare’s New Power to Negotiate Lower Drug Prices
-
Bloomberg
Novartis Allows Generic Leukemia Drug Production in Seven Nations
-
FiercePharma
J&J is letting go of 64 staffers in Manhattan
-
Reuters
Falling demand for COVID boosters puts price hikes on the table
Oct 19, 2022
-
CNBC
FDA authorizes Novavax’s Covid shots as mix-and-match booster to Pfizer or Moderna
-
Bloomberg Law
Better Antibiotic Trials Sought as Congress Weighs Funding Bill
-
Endpoints News
FDA commissioner on accelerated approval reforms: ‘Need to address as soon as possible’
-
Wired
How Iodine Pills Can—and Can’t—Help Against Radiation
Oct 18, 2022
Oct 17, 2022
-
Associated Press
Biden pushing lower prescription drug costs in midterm press
-
FiercePharma
Novartis dealt another blow in ongoing Gilenya patent feud
-
MarketWatch
Milestone Pharmaceuticals Sees Positive Results in Etripamil Trial
-
Reuters
Bill & Melinda Gates Foundation pledge $1.2 billion to eradicate polio
Oct 14, 2022
Oct 13, 2022
-
The New York Times
After Giving Up on Cancer Vaccines, Doctors Start to Find Hope
-
Business Insider
CRISPR Gene-Editing Biotechs Keep Growing Despite Downturn
-
Financial Times
Beijing’s failure to import mRNA Covid jabs ‘mind-boggling,’ says BeiGene executive
Previous
